Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Johnson & Johnson launches Bay Area science and technology campus

By Brian Buntz | September 20, 2022

JanssenJohnson & Johnson (NYSE:JNJ) has opened an almost 200,000 ft2 science and technology campus in the San Francisco Bay Area.

The new facility more than doubles the company’s presence in the Bay Area, which has been a hub for life sciences innovation for decades. Up to 400 employees will work at the facility.

“This campus is our downpayment in our ability to innovate for the future,” Johnson & Johnson CEO Joaquin Duato said today at an opening ceremony for the facility in Brisbane, California.

The new science and technology campus will unite the drug and device maker’s scientific and technological capabilities by housing Janssen Research and Development (R&D), Johnson & Johnson Innovation and Johnson & Johnson Technology under one roof.

The new site was designed to spur internal and external collaboration, said site lead James Merson, Janssen’s global therapeutic area head for infectious diseases.

“The San Francisco Bay Area is unique in the respect that we have Silicon Valley,” said Merson, who added that the region is “well-recognized as a hub for science and technology, data science entrepreneurship and innovation.”

A focus on data science has become increasingly vital for Janssen. The company has made significant investments in machine learning and AI in recent years. As a result, data scientists have been “completely integrated into how we discover and develop our medicines,” Merson added. “They’re enabling us to go much faster than we did previously.”

Merson expects that the new science and technology campus will help the company continue to recruit “world-class data scientists.”

The site’s R&D focus includes gene and RNA therapies and emerging therapies for retinal and infectious diseases. “This was a fit-for-purpose building,” Merson said. “We were able to take the opportunity to upgrade the equipment. And we have the appropriate biocontainment facilities.”

Janssen's new site in Brisbane, California

Janssen has outfitted the new site in Brisbane, California with state-of-the-art equipment

Uniting R&D, innovation and technology activities in a single campus could accelerate drug discovery and development. “I think that colocation will allow us to do R&D In a way where we can discover, develop and deliver transformative medicines to improve healthcare worldwide,” Merson said. “We think we can do this more efficiently, faster by being colocated.”

Data scientists and scientists sit on the same floor on the new campus. “When people can articulate a problem to solve, they solve it more effectively when they’re colocated,” Merson said.

Giving data scientists access to research scientists can help them “learn faster about the scientific challenges facing us for various diseases,” Merson said.

The new Janssen facility, for instance, is working to develop a functional cure for Hepatitis B.

“We work with our data science colleagues to ensure that we can properly characterize patients using bioinformatics,” Merson said. “That then allows us to run our clinical studies more efficiently.”

Because clinical trials are frequently a relatively slow process in drug discovery and development, “anything we can do to expedite and make our clinical trials more efficient is a good thing,” he added.

While Janssen has increased its reliance on video conferencing software such as Zoom during the pandemic like many other companies, in-person collaboration remains formidable in sparking creativity. “You definitely see a tick up in the ability of teams to solve a problem when they’re physically working together,” Merson said.


Filed Under: Drug Discovery and Development
Tagged With: Janssen, Johnson & Johnson
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Data analytics tools help doctors analyze trends in patient outcomes and population health.
External comparator studies: What researchers need to know to minimize bias
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE